Evidence map›Paper›PMID 18694335›Full record

ArticleThe Journal of infectious diseases2008

Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Ashraf S Ibrahim, Teclegiorgis Gebremariam, Mingfu Liu, Georgios Chamilos, Dimitrios Kontoyiannis, Richard Mink, Kyung J Kwon-Chung, Yue Fu, Christopher D Skory, John E Edwards and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 75 citations in OpenAlex.

  1. Phylogenetically diverse MucoralesMicrobial genomics · 2026
    Article
  2. Article
  3. Article
  4. Lineage-specific endosymbiosis in Mucorales: restriction ofCurrent research in microbial sciences · 2026
    Article
  5. Review
  6. Review
  7. Mixed Culture Cultivation in Microbial Bioprocesses.Advances in biochemical engineering/biotechnology · 2025
    Review
  8. Article
  9. Article
  10. Molecular mechanisms that govern infection and antifungal resistance in Mucorales.Microbiology and molecular biology reviews : MMBR · 2024
    Review
  11. AlternativeFrontiers in cellular and infection microbiology · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Plant Growth-Promoting Ability of MycorrhizalFrontiers in microbiology · 2022
    Article
  20. Novel Secreted Peptides FromFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Ashraf S IbrahimLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA. ibrahim@labiomed.org
Teclegiorgis Gebremariam
Mingfu Liu
Georgios Chamilos
Dimitrios Kontoyiannis
Richard Mink
Kyung J Kwon-Chung
Yue Fu
Christopher D Skory
John E Edwards
Brad Spellberg
Harbor–UCLA Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, Los Angeles · USIllinois Department of Agriculture · USNational Institutes of Health · USUCLA Medical Center · US

Funding

Novel Toxins and Receptors in Mucormycosis Pathogenesis and TreatmentR01AI063503 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2025
$7.3M
Adrenergic Antagonism During Murine CandidiasisK08AI060641 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI SPELLBERG, BRAD J · 2004 to 2008
$625k
BASIC STUDIES ON CANDIDA SPECIESZ01AI000657 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI KWONCHUNG, KYUNG · 1992 to 2008
$472k
Novel Antifungal Strategies for Lethal MucormycosisR21AI064716 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI IBRAHIM, ASHRAF S. · 2006 to 2007
$367k
Intramural NIH HHS Z01 AI000657NIAID NIH HHS K08 AI060641NIAID NIH HHS R01 AI063503NIAID NIH HHS R21 AI064716
6 · The paper itself

Abstract

Environmental isolates of the fungus Rhizopus have been shown to harbor a bacterial endosymbiont (Burkholderia) that produces rhixozin, a plant mycotoxin. We sought to define the role of rhizoxin production by endosymbionts in the pathogenesis of mucormycosis. Endosymbiotic bacteria were identified by polymerase chain reaction in 15 (54%) of 28 clinical isolates of Zygomycetes, with 33% of the bacterial strains showing 87% identity to Burkholderia 16S rDNA. The presence of rhizoxin in myclial extracts from fungi harboring bacteria was confirmed by high-performance liquid chromatography analysis. However, fungal strains with or without endosymbionts did not differ in their ability to cause endothelial cell injury in vitro, nor did antibiotic-mediated eradication of endosymbionts and rhizoxin production decrease the virulence of fungal strains in mice or flies. In summary, although bacterial endosymbiosis is widely detected in clinical isolates of Zygomycetes, including Rhizopus oryzae strains, we found no evidence that bacterial endosymbionts and rhizoxin contribute to the pathogenesis of mucormycosis in the models studied.

Indexed as

SymbiosisAnimalsBurkholderiaEndothelial CellsHumansMacrolidesMaleMiceMice, Inbred BALB CMucorMucormycosisRhizopusMacrolidesrhizoxin

Identifiers

PMID18694335
PMCPMC2729545
OpenAlexW2144993665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.